The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! About 751,304 shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 38.83% since March 8, 2016 and is uptrending. It has outperformed by 29.51% the S&P500.
The move comes after 9 months positive chart setup for the $3.33B company. It was reported on Oct, 11 by Barchart.com. We have $37.85 PT which if reached, will make NASDAQ:ACAD worth $1.27 billion more.
Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on November, 3. They expect $-0.60 earnings per share, down 53.85% or $0.21 from last year’s $-0.39 per share. After $-0.63 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
Out of 4 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. ACADIA Pharmaceuticals has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Piper Jaffray downgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Friday, August 7 to “Overweight” rating. Vetr upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Monday, August 10 to “Hold” rating. The rating was initiated by Leerink Swann on Tuesday, October 4 with “Mkt Perform”. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Overweight” rating by Piper Jaffray on Friday, January 22. Leerink Swann downgraded the shares of ACAD in a report on Tuesday, May 3 to “Market Perform” rating. On Friday, September 4 the stock rating was maintained by JP Morgan with “Buy”. Cowen & Co maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Sunday, August 9 with “Outperform” rating. Piper Jaffray downgraded the stock to “Neutral” rating in Friday, August 7 report. As per Thursday, August 27, the company rating was upgraded by Piper Jaffray. The firm has “Buy” rating by Needham given on Friday, August 7.
According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio fall, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Allianz Asset Management Ag has 131,946 shares for 0% of their US portfolio. Hanseatic Mngmt Svcs Inc accumulated 31,025 shares or 0.38% of the stock. Martingale Asset Mgmt Lp accumulated 0.01% or 17,544 shares. The Arizona-based Tci Wealth Advsrs has invested 0.02% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Tiaa Cref Mngmt Ltd owns 383,440 shares or 0.01% of their US portfolio. The California-based Eam Ltd Liability Company has invested 0.32% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Vanguard Group Inc last reported 6.37 million shares in the company. Moreover, Manufacturers Life Insurance Com The has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 3,092 shares. D E Shaw Communications reported 7,820 shares or 0% of all its holdings. International Gp has 2,229 shares for 0% of their US portfolio. Moreover, Cowen Grp Incorporated has 0.04% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 17,500 shares. Clearbridge Investments Ltd Liability Corporation accumulated 0% or 500 shares. Hollencrest Secs Limited Liability Corp last reported 0.06% of its portfolio in the stock. Winslow Evans & Crocker Inc holds 0% or 4,400 shares in its portfolio. Royal Natl Bank Of Canada accumulated 613,300 shares or 0.01% of the stock.
Insider Transactions: Since April 18, 2016, the stock had 2 buys, and 2 sales for $41.34 million net activity. Another trade for 16,000 shares valued at $560,033 was made by Baity Glenn on Monday, July 11. 33,697 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares with value of $1.13M were sold by Iversen Leslie L. $32,970 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was bought by HARRIGAN EDMUND. Shares for $43.00 million were bought by BAKER BROS. ADVISORS LP on Wednesday, August 10.
More news for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were recently published by: Fool.com, which released: “Why ACADIA Pharmaceuticals Tumbled 13.3% in August” on September 11, 2016. Nasdaq.com‘s article titled: “Acadia Pharmaceuticals Enters Oversold Territory (ACAD)” and published on October 05, 2016 is yet another important article.
ACAD Company Profile
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.